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Abstract: Sphingolipid metabolism starts with the biosynthesis of ceramide, a bioactive lipid
and the backbone for the biosynthesis of complex sphingolipids such as sphingomyelin and
glycosphingolipids. These are degraded back to ceramide and then to sphingosine, which enters
the ceramide–sphingosine-1-phosphate signaling pathway or is further degraded. Several enzymes
with multiple catalytic properties and subcellular localizations are thus involved in such metabolism.
Hereditary defects of lysosomal hydrolases have been known for several years to be the cause of
lysosomal storage diseases such as gangliosidoses, Gaucher disease, Niemann–Pick disease, Krabbe
disease, Fabry disease, and Farber disease. More recently, many other inborn errors of sphingolipid
metabolism have been recognized, involving enzymes responsible for the biosynthesis of ceramide,
sphingomyelin, and glycosphingolipids. Concurrently, epidemiologic and biochemical evidence has
established a link between Gaucher disease and Parkinson’s disease, showing that glucocerebrosidase
variants predispose individuals to α-synuclein accumulation and neurodegeneration even in the
heterozygous status. This appears to be due not only to lysosomal overload of non-degraded
glucosylceramide, but to the derangement of vesicle traffic and autophagy, including mitochondrial
autophagy, triggered by both sphingolipid intermediates and misfolded proteins. In this review,
old and novel disorders of sphingolipid metabolism, in particular those of ganglioside biosynthesis,
are evaluated in light of recent investigations of the link between Gaucher disease and Parkinson’s
disease, with the aim of better understanding their pathogenic mechanisms and addressing new
potential therapeutic strategies.
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1. Introduction
Sphingolipid metabolism starts in the endoplasmic reticulum (ER) with the condensation of
serine and palmitic acid, producing 3-keto-dihydrosphingosine (also named 3-keto-sphinganine),
and it continues through successive enzymatic reactions leading to the synthesis of ceramide [1]
(Figure 1). Ceramide plays several roles in cell homeostasis, itself acting as a regulator or through
the generation of other bioactive lipids such as ceramide-1-phosphate and sphingosine-1-phosphate
(S1P) [2]. Nevertheless, a large amount is used as the backbone for the biosynthesis of sphingomyelin
(SM) and glycosphingolipids (GSLs) (Figure 2). In particular, ceramide is acted upon by UGT8,
galactosylceramide (GalCer) synthase (see Tables 1–3 for enzyme symbols) in the ER [1], and SGMS,
SM synthase [3] or UGCG, glucosylceramide (GlcCer) synthase [4] in the Golgi apparatus. GlcCer may
undergo many different further glycosylations, giving rise to a plethora of GSLs, depending on the
specific glycosyltransferase machinery present in the various cell types. These include gangliosides,
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globosides, and other neutral compounds (Figure 2). Ceramide, SM, and GSLs flow through the
Golgi to the plasma membrane or other organelles (such as mitochondria in the case of ceramide)
via vesicular-mediated [5] or protein-mediated traffic [6]. The plasma membrane is considered the
main destination of such compounds, which may also be delivered outside the cell in the form of
microvesicles [7] or channeled along the endocytic pathways toward phagosomes and lysosomes. In the
lysosomes, complex sphingolipids are stepwise degraded to fatty acids and sphingosine (Figures 1
and 2). Sphingosine reaches the ER, where it enters the Cer–S1P signaling pathway. S1P can be also
degraded to phosphoethanolamine and 2-hexadecenal [1] (Figure 1). Defects of specific lysosomal
hydrolases (Table 1) involved in this process have been known for several years and constitute the
main group of lysosomal storage disorders due to inborn errors of metabolism [8]. These include the
gangliosidoses, Niemann–Pick disease, Fabry disease, Krabbe disease, Gaucher disease, and Farber
disease. More recently, defects of several enzymes responsible for the biosynthetic steps (Tables 2
and 3) were found to be associated with human diseases: these include variants of serine palmitoyl
transferases (SPTLC) [9,10], 3-keto-dihydro-sphingosine reductase (KDSR) [11–13], dihydro-ceramide
synthases (CERS) [14–18], dihydroceramide desaturase (DEGS) [19–21], sphingomyelin synthases
(SGMS) [22,23], GlcCer synthase (UGCG) [24], GM3 synthase (ST3GAL5), GM2/GD2/GA2 synthase
(B4GALNT1), and CMP-Sial: GlcNAcβ1,3(4) sialyltransferase (ST3GAL3) [25]. The latter four enzymes
are glycosyltransferases and, thus, the related diseases belong to the wide family of the congenital
disorders of glycosylation (CDG) [26]. It is worth noting that some enzymes of sphingolipid metabolism
exist in different isoforms representing different gene products, sometimes with different subcellular
localization, as in the case of ceramidases, ceramide synthases, sphingomyelinases, and SM synthases
(Tables 1–3). It is not surprising that disorders involving different isoforms may produce very
different clinical phenotypes. Variants of CERS1 and -2 result in a myoclonus epilepsy [14,15,17],
while CERS3 variants determine a form of ichthyosis [16]. Glucocerebrosidase (GBA) variants are
responsible for Gaucher disease (GD) [27], while GBA2 variants result in hereditary spastic paraplegia
46 (HSP46) [28]. Acid ceramidase ASAH1 deficiency is the cause of Farber disease [29], while alkaline
ceramidase (ACER3) variants are responsible for progressive leucodystrophy [30]. Many of such
disorders result in extremely heterogeneous clinical syndromes, in terms of both symptoms and severity,
and some give rise to clinical features overlapping those of disorders involving totally unrelated
genes [31]. GD is the most relevant example of the former. The clinical presentation ranges from a mild
visceral impairment detectable in adulthood to a severe neurologic impairment that is lethal by early
childhood, without a clear relationship with the underlying mutation or the amounts of residual enzyme
activity [27,32,33]. On the other hand, B4GALNT1-CDG is one of about 70 known genetic defects
determining an inherited spastic paraplegia [34], and ST3GAL3-CDG is reported as one of the many
conditions causing West syndrome, potentially evolving to Lennox–Gestaut syndrome [35]. Many
such disorders are typically transmitted in an autosomal recessive manner (see Tables 1–3). However,
emerging data show that heterozygous carriers of glucocerebrosidase GBA [33], sphingomyelinase
SMPD1 [36], galactocerebrosidase (GALC) [37], and α-galactosidase (GLA) [38] variants are as much
at risk for neurodegenerative diseases such as synucleopathies and multiple sclerosis as those with
recessive homozygotes.
The purpose of this review is to evaluate recent data concerning disorders of sphingolipid
metabolism where the pathogenic role played by the loss of function of enzymes appears unable to
explain the whole picture, while other mechanisms seem to cooperate with the clinical phenotype.
Among them, the emerging candidates include the impairment of vesicle traffic in the context of
autophagy/lysosome function and altered trafficking and metabolism of the variant proteins. In this
regard, the data on GD as the main risk factor for Parkinson’s disease (PD) suggest that the GD/PD
connection may represent a pathogenic paradigm able to shed light on other disorders of sphingolipid
metabolism. In particular, we focus on those affecting ganglioside biosynthesis as the disorders where
such aspects could be relevant. This is interesting not only to better understand sphingolipid biology
and the disease pathogenesis, but to address novel potential therapeutic strategies.
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Figure 1. Biosynthesis and degradation of ceramide. SPTLC, serine palmitoyl transferase; KDSR, 3-
keto-dihydro-sphingosine reductase; CERS, dihydroceramide synthase; DEGS, dihydroceramide 
desaturase; ASAH, acid ceramidase; ACER, alkaline ceramidase; SPHK, sphingosine kinase; SGPL1, 
sphingosine lyase. For simplicity, only stearic acid is depicted as the acyl chain of ceramides, but 
longer fatty acids can be added by different CERSs. 
Figure 1. Biosynthesis an degradation of ceramide. SPTLC, serine palmitoyl transferase; KDSR,
3-keto-dihydro-sphingosine reductase; CERS, dihydroceramide synthase; DEGS, dihydroceramide
desaturase; ASAH, acid ceramidase; ACER, alkaline ceramidase; SPHK, sphingosine kinase; SGPL1,
sphingosine lyase. For si plicity, only stearic acid is depicted as the acyl chain of ceramides, but longer
fatty acids can be added by different CERSs.
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Figure 2. Biosynthesis and degradation of complex glycosphingolipids. Monosaccharides are 
depicted according to the current representation: Glc, glucose; Gal, galactose; GlcNAc, N-
acetylglucosamine; GalNAc, N-acetylgalactosamine; Sia, sialic acid. Enzyme symbols are according 
to the HUGO nomenclature (see Table 2; Table 3 for enzyme details). UGT8, GalCer synthase; GALC, 
galactocerebrosidase; SGMS, sphingomyelin synthase; SMPD, sphingomyelinase; UGCG, GlcCer 
synthase; GBA, glucocerebrosidase; B4GALT, β1,4-galactosyltransferase; GLB1, β-galactosidase; 
A4GALT, α1,4-galactosyltransferase; GLA, α-galactosidase; B3GALT, β1,3-GalNActransferase; Hex, 
hexosaminidase; B3GNT, β1,3-GlcNAc transferase; B3GALT, β1,3-galactosyltransferase; ST3GAL, 
galactoside-α2,3-sialyltransferase; NEU, neuraminidase (sialidase). Lc3, lactotriaosylceramide 
GlcNAcβ1,3Galβ1,4GlcCer; Lc4, lactotetraosylceramide; LM1, sialyllactotetraosylceramide, 
Siaα2,3Galβ1,3GlcNAcβ1,3Galβ1,4GlcCer; Gb3, globotriaosylceramide Galα1,3Galβ1,4GlcCer; Gb4, 
globotetraosylceramide GalNAcβ1,3Galα1,3Galβ1,4GlcCer. 
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Figure 2. Biosynthesis and degradation of complex glycosphingolipids. Monosaccharides are depicted
according to the current representation: Glc, glucose; Gal, galactose; GlcNAc, N-acetylglucosamine;
GalNAc, N-acetylgalactosamine; Sia, sialic acid. Enzyme symbols are according to the HUGO
nomenclature (see Table 3; Table 2 for enzyme details). UGT8, GalCer synthase; GALC,
galactocerebrosidase; SGMS, sphingomyelin synthase; SMPD, sphingomyelinase; UGCG, GlcCer
synthase; GBA, glucocerebrosidase; B4GALT, β1,4-galactosyltransferase; GLB1, β-galactosidase;
A4GALT, α1,4-galactosyltransferase; GLA, α-galactosidase; B3GALT, β1,3-GalNActransferase; Hex,
hexosaminidase; B3GNT, β1,3-GlcNAc transferase; B3GALT, β1,3-galactosyltransferase; ST3GAL,
galactoside-α2,3-sialyltransferase; NEU, neuraminidase (sialidase). Lc3, lactotriaosylceramide
GlcNAcβ1,3Galβ1,4GlcCer; Lc4, lactotetraosylceramide; LM1, sialyllactotetraosylceramide,
Siaα2,3Galβ1,3GlcNAcβ1,3Galβ1,4GlcCer; Gb3, globotriaosylceramide Galα1,3Galβ1,4GlcCer; Gb4,
globotetraosylceramide GalNAcβ1,3Galα1,3Galβ1,4GlcCer.
2. GBA Variants, GD, PD, and How They Interplay
GD is a lysosomal storage disorder caused by recessive mutations in the GBA gene, coding the
β-galactosidase responsible for the degradation of GlcCer to glucose and ceramide [39]. Reduced GBA
activity leads to the accumulation of GlcCer and/or its immediate by-product glucosylsphingosine
(GlcSph), formed by the action of acid ceramidase on GlcCer (Figure 3). GBA is synthesized in the ER
as a 536- or 516-amino-acid protein, containing a short signal peptide of 19 or 39 amino acids at the
N-terminus that is trimmed soon after translation [40]. The residual 497 amino acid peptide is then
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glycosylated [41] and recognized by the SCARB2 (scavenger receptor class B member 2) system [42].
The GBA/SCARB2 complex [43] experiences traffic through the Golgi apparatus and endocytic vesicles
and then reaches the lysosomes, which are the sites of action. In the lysosomes, GBA activity is
also controlled by the activator protein saponisin C. Another glucocerebrosidase is coded by the
human genome, GBA2, which has a microsomal localization and is not involved in GD but instead
is responsible for a form of HSP, reported as HSP46 [28,44] (Table 1). From a clinical point of view,
patients suffering GD present two main distinct syndromes [8,27]. Type 1 GD is characterized by the
involvement of several visceral organs without that of the central nervous system, while types 2 and
3 present serious neurologic symptoms and are defined as neuronopathic GD. Symptoms of type 1
disease appear in adulthood and classically include anemia, hepatosplenomegaly, bone pain, and other
inflammatory signs. The inflammatory effect of GlcCer accumulation was recently proposed to be
the consequence of complement C5a activation [45]. However, more recent reports identified patients
with type 1 GD developing peripheral polyneuropathy at an older age [33]. Moreover, a subset of
patients was recently reported to present mild but distinctive intellectual impairment, suggesting an
involvement of the central nervous system [46,47]. Conversely, neuronopathic disease is much more
severe: early onset of neurologic symptoms includes supranuclear gaze palsy, cognitive impairment
(frequently, features of oppositional defiant disorder), seizures, various muscular problems, and even
sudden death. Rapid progression of the disease with death in early childhood is characteristic of type
2 disease, while in type 3 the progression is slower. Type 2 and 3 diseases are also suggested to be
the more evident forms of a spectrum disease [33]. About 300 different mutations have been reported
to affect the GBA gene. Some of them, such as L444P and N370S, are more frequent and account for
several cases. There is a wide variety of mutation frequency between ethnicities. For instance, up to 1 in
every 15 persons is considered a carrier of a GBA mutation in the Ashkenazi Jewish population, versus
1 in every 100 for others [27,48]. Despite several attempts to find a correlation between individual
mutations and the clinical syndrome, none have been firmly established so far, and patients affected
by the same mutation present a large variability of symptoms [27,32]. Data of the residual enzyme
activity and its potential role as a predictor of disease severity are also contradictory [33,49]. Both
the common L444P and N370S variants are associated with a similar strong reduction in enzyme
activity, about 80–90% compared with the wild type enzyme [50]. Conversely, the N370S variant is
more frequently associated with the type 1 disease and a mild or very mild phenotype, while the L444P
variant is associated with type 3 disease and a severe neuronopathic phenotype in general. Some
reports indicate that GBA variants are instable or misfolded proteins, which do not undergo normal
intracellular traffic, irrespective of the amount of catalytic activity maintained [39,50], suggesting a role
for proteostasis in GD. A very intriguing issue in this field is the epidemiological evidence, established
about 10 years ago, that GBA mutations are the major genetic risk factors for the development of
PD in elderly people [51]. Such a risk is associated not only with GD but with the carrier status
of heterozygous GBA variants, as proven in the family members of GD patients. The molecular
mechanism linking GBA mutations to PD appears complex. Experimental evidence indicates that
reduced GBA activity and concurrent accumulation of GlcCer takes places in normal aging of the
mouse brain [52]. In humans, reduced expression and activity of GBA was found in the substantia
nigra of the post-mortem brains of patients suffering from PD, both sporadic and associated with
GBA mutations [53]. Pathologically, the hallmark of PD is the presence of Lewy bodies in affected
cells, consisting of the accumulation of α-synuclein aggregates in the cells. The derangement of
α-synuclein metabolism in PD is suspected to be the consequence of impaired autophagy and lysosome
clearance [50,54]. The interaction between GBA variants, with or without loss of GBA activity, and
α-synuclein accumulation has been intensively studied in neuronal cultures and in animal models.
Deposition of α-synuclein aggregates impairs vesicle trafficking [55], which disrupts traffic of GBA and
other hydrolases to the lysosomes, favoring further α-synuclein accumulation and self-maintenance
of the pathogenic process [54]. Accordingly, double transgenic mice heterozygous for a null GBA
allele and expressing human α-synuclein showed a relevant disruption of dopaminergic neurons
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associated with the accumulation of GlcSph but not GlcCer [56]. Comparable results were found by
analyzing post-mortem brains of patients suffering sporadic PD or dementia with Lewy bodies, where
the levels of α-synuclein were inversely correlated with those of the GBA protein and directly with
those of GlcSph [57]. On this basis, it was hypothesized that parallel reduction of GlcCer synthase
activity, with concurrent lowering of the GSL levels and, in turn, the GlcCer load into the lysosomes,
may prevent such derangement. Studies on GlcCer synthase inhibitors able to pass the blood–brain
barrier are in progress as novel therapeutic approaches [58]. In a cellular model of GBA deficiency,
obtained by CRISP/Cas9 genome editing of HEK-293 cells, decreased ceramide levels were found to be
associated with impaired secretory autophagy and intracellular α-synuclein accumulation [59], which
is prevented by exogenous ceramide supplement or acid ceramidase inhibition. These results point
out that the relative loss of GBA activity and consequent accumulation of GlcCer or its by-product
GlcSph, or ceramide depletion, are pathogenic, impairing lysosomal function and autophagy [60]
and, in turn, triggering the development of PD. Moreover, GBA deficiency may promote the spread
of protein aggregates through extracellular vesicles [61]. On the other hand, other data suggests
that GBA activity and GlcCer/GlcSph/ceramide levels are not necessary to determine the increased
risk of developing PD. Carriers of the E326K GBA variant, which maintain substantial enzymatic
activity, present increased risk of developing PD, although such mutation does not determine GD in
the homozygotes [62]. Impaired autophagy due to GBA mutations was suggested to occur and to affect
the clearance of damaged mitochondria as a consequence of altered proteostasis [50,63]. In mouse
and cellular models carrying the L444P GBA variant, the loss of lysosomal enzyme activity blocks
the degradation of autophagic cargos, whereas the variant GBA protein impairs autophagy induction
and the priming of damaged mitochondria, indicating a gain of toxic function for the mutant protein.
This effect may be attributed to the ER retention of the variant GBA protein, resulting in an unfolded
protein response [64]. In a mouse model, overexpression in the striatum of the N370S GBA variant
affects α-synuclein and, in particular, its secretion through exosomes, while the simple inhibition of
enzyme activity by conditurol-β-epoxide does not [65].
Enzyme replacement and substrate reduction therapies are currently approved and used in clinical
practice for the treatment of GD patients suffering visceral symptoms of the disease [66]. They are
ineffective in neuronopathic GD because they are unable to cross the blood–brain barrier. In light of the
emerging complexity of GD pathogenesis, the above-mentioned mechanisms of disease also provide
new potential targets of therapeutic approaches [66,67]. In particular, heterogeneity in the clinical
outcome between patients harboring the same genotype introduced the concept of genetic modifiers of
the disease. They are defined as genes able to alter the clinical phenotype of a disease, modifying the
penetrance, expressivity, dominance, or pleiotropy of the causative defect. Several have been identified
for GD, some acting directly on the GBA pathway (GBA2, SCARB2, UGCG), and others regulating
lysosomal function (TFEB, transcription factor EB) or downstream pathways [68]. Small molecules
able to cross the blood–brain barrier are able to increase TFEB activity, inhibit UGCG [58], or restore
autophagy [69], representing promising examples of such novel drugs.
3. Other Diseases of Sphingolipid Metabolism Determining or Predisposing Individuals to
Neurodegenerative Disorders
The growing and converging evidence supporting lysosome involvement in PD and the
relevance of GBA variants as the main genetic risk factors for developing the disease have
prompted several researchers to study potential connections between other lysosomal diseases
and neurodegenerative disorders (data are summarized in Table 1). The first association was proposed
between sphingomyelinase SMPD1 variants, causing Niemann–Pick disease types A and B and
PD [70], and received further confirmations suggesting that reduced sphingomyelinase activity led to
α-synuclein accumulation [71]. Niemann–Pick disease type C is clinically similar to Niemann-Pick
disease type A, but is determined by mutations of a different gene (NPDC1, neural proliferation
differentiation and control protein 1), coding a protein regulating endocytic transport in late endosomes
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and lysosomes. Interestingly, inhibition of GBA2 improves lysosomal function in fibroblasts from
Niemann-Pick disease type C patients [72]. Thus, the question rose as to whether mutations of other
genes responsible for known lysosomal storage diseases predispose patients to PD. Analysis of a large
whole exome sequencing dataset available for PD [73] suggested the association of the disease with
three proteins responsible for lysosomal diseases in addition to GBA and SMPD1. They include ASAH1
(acid ceramidase, causing Farber disease), CLN10 (cathepsin-D, a lysosomal aspartyl proteinase causing
neuronal ceroid lipofuscinosis), and SLC17A5 (sialin, causing Salla disease). The latter is involved in the
transport of the sialic acid residues released by the action of sialidases on gangliosides and glycoproteins
out of lysosomes [74]. Of note, Farber disease is a typical spectrum disease where patients carrying the
same mutation present very different clinical features (reviewed in [29]) (Table 1). Neuronal ceroid
lipofuscinosis is a neurodegenerative disorder determined by the mutations of at least 13 different genes,
all somewhat involved in autophagy [75]. Recent studies onα-galactosidase A (GLA) deficiency, causing
Fabry disease, an X-linked disorder causing systemic symptoms, have suggested a possible association
between GLA mutations and PD or multiple sclerosis [38,76]. Moreover, GLA activity was reported to
be lower in PD cases compared to controls [77]. Similarly, galactocerebrosidase (GALC) mutations,
causing Krabbe disease, are studied as potentially being related to neurodegeneration/multiple sclerosis
and synucleopathies [78–80]. In this regard, lysosphigolipids (Figure 3) formed in the disease, and even
in GD, Fabry disease, Niemann-Pick disease, and GM1 gangliosidosis (Table 1), were reported to affect
endolysosomal transport and pH, leading to the possible formation of α-synuclein aggregates [81,82].
Signs of Parkinsonism are now considered to be detectable in various inherited metabolic disorders in
addition to GD and Niemann Pick disease [83]. Recent studies highlight the potential link between PD
and sphingolipids, particularly gangliosides. They were found to promote α-synuclein aggregation
in vitro [84]. In cellular models, accumulation of gangliosides due to reduced activity of GBA variants
prevented the formation of stable α-synuclein tetramers, and pharmacologic (miglustat) inhibition of
GSL biosynthesis restored α-synuclein stabilization [85]. Reduced expression of galactosyltransferase
B3GALT4 and sialyltransferase ST3GAL2, as detected by in situ hybridization, was found to occur
specifically in neuromelanin producing neurons of the brains of PD patients [86]. Plasma levels of
GM3 were found to be increased in PD patients [87].
It is also interesting to consider the data now available from inherited diseases of sphingolipid
metabolism very recently reported (Tables 2 and 3). In the defects of serine palmitoyl transferases
SPTLC1-2 and dihydroceramide desaturase DEGS1, causing forms of hereditary sensory neuropathy
type 1 and hypomyelinating leukodystrophy, respectively, the presence of potentially toxic compounds
is suspected to be involved in the disease pathogenesis. In particular, deoxysphingolipids formed by
SPTLC1-2 variants were found to exert mitochondrial toxicity [10], and increased amounts of reactive
oxygen species (ROS) were detected in fibroblasts from patients carrying DEGS1 variants. Interestingly,
pharmacological inhibition of CERS prevents ROS accumulation [21].
Heterozygous variants of sphingomyelin synthase SGMS2, an enzyme coding a plasma membrane
form of sphingomyelin synthase, were found associated with the clinical picture of Osteoporosis with
Skeletal Dysplasia. Interestingly, the main clinical signs are restricted to the bones, but a spectrum
of mild or very mild neurologic symptoms were detected. Disease severity appeared dependent on
mislocalization of enzyme variants more than on levels of residual activity [23].
Together, these data suggest that sphingolipid metabolism interacts with cellular homeostasis
through several mechanisms that can be affected by enzyme mutations, as recapitulated by the ability
of GBA variants to determine a spectrum disease, including neurodegenerative disorders such as PD.
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4. Specific Diseases of Ganglioside Biosynth sis Determining Neurodegenerative Disorders
4.1. GM2 Synthase Deficiency (B4GALNT1-CDG), HSP26, and Other HSPs
B4GALNT1 is the enzyme necessary to extend all ganglio-series gangliosides [88,89] (Figure 2).
Consequently, its impairment leads to a lack of complex gangliosides and accumulation of GM3 and
GD3. Twelve pathogenic variants of the gene have been reported so far in 12 families, involving
38 individuals, all showing a form of complex HSP previously referred to as HSP26 [90–92]. The
syndrome is characterized by late onset of motor impairment of the legs accompanied by mild to
moderate cognitive impairme t, s metime associated with psychiatric illn ss and/or non-neurological
symptoms such as pes cavus or hypogonadism in males (Table 2). Very recently [93], it has been
reported that nine out of 11 tested mutations lead to a complete loss of enzyme activity, while two
variants (R300C and R228*) maintain a small but detectable residual activity in vitro. Three variants
appeared not detectable by western blot, while the other eight were found to be correctly localized to
the Golgi apparatus by confocal microscopy, suggesting that the loss of function is the main pathogenic
event. This hypothesis is also supported by the evidence that b4galnt1 KO mice present a similar
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phenotype [94], although in some but not all cases [95]. However, HSP is due to the defect of a
plethora of different genes [34]. Two of them directly involve sphingolipid metabolism in addition to
B4GALNT1: GBA2, responsible for HSP46 [28], and FA2H, involved in HSP35 [96] and coding for fatty
acid 2-hydroxylase [97]. Interestingly, HSP11 is due to the loss of function of spatacsin, a product of the
SPG11 gene, which is involved in lysosome membrane recycling. In the spg11 KO mouse model [98],
loss of spatacsin impairs ganglioside clearance from the lysosome and determines the accumulation of
autophagy markers. In addition, neurodegeneration was stimulated by the accumulation of gangliosides
in cultured neurons and was prevented by miglustat. The same authors were also able to reduce motor
impairment by inhibiting ganglioside biosynthesis in the HSP11 zebrafish model.
4.2. GM3 Synthase Deficiency (ST3GAL5-CDG)
ST3GAL5 displays unique GM3 synthase activity, being responsible for the biosynthesis of
ganglio-series gangliosides of the a-, b-, and c-series, with the exception of 0-series gangliosides, such
as GM1b and GD1α [99] (Figure 2). Five different pathogenic mutations have been reported so far,
all causing a very severe syndrome characterized by normal pregnancy and delivery but early onset
of neurological symptoms including drug-resistant epilepsy, failure to thrive, and impaired hearing
and vision. Growth delay and progressive regression occur, giving rise to deafness, blindness, and
general motor and cognitive impairment [25,100]. While the original description of a few families
suggested a potential different degree of pathogenicity between mutations [101–103], a recent survey
of several cases affected by the same R288* non-sense mutation indicated the opposite [104]. Some
of these patients lack clinical seizures or were initially able to crawl, as originally reported only for
two siblings carrying the compound C195S/G201A mutations [103]. Accordingly, we have recently
shown that all reported mutations abolish any detectable enzyme activity, without differences between
the single mutations [100]. Moreover, we also found a normal localization of the variant ST3GAL5s.
Altogether, this data is in agreement with the current hypothesis that the total absence of gangliosides
is responsible for the general lack of neuron homeostasis, leading to inflammation and, consequently,
loss of several functions [105]. However, many patients present mildly elevated blood lactate and their
cells have an impaired respiratory chain function [25,100]. In this context, the hypothesis that impaired
autophagy and, in particular, mitophagy may be involved in the disease pathogenesis should be kept
in mind. The enormous distance between the devastating human syndrome and the very mild KO
mouse model [106,107] corroborates such a suggestion.
4.3. ST3GAL3-CDG, Non-Syndromic Intellectual Disability and West Syndrome
ST3GAL3 is considered the enzyme responsible for the α2,3 sialylation of galactose preferentially
β1,3 linked to GlcNAc in several glycoconjugates, including glycoproteins carrying both N- and O-
glycans and GSLs of the lacto-series [108,109]. Data obtained in vitro with the mouse enzyme suggested
a strong preference for the Galβ1,3GlcNAc acceptor sequence [110], ruling out the ability to use the
Galβ1,3GalNAc sequence, including ganglio-series gangliosides. Conversely, double st3gal2/st3gal3
KO mice exhibited substantial loss of GD1a and GT1b gangliosides in their brain, not found in single
st3gal2 KO animals, suggesting the ability of the enzyme to use the Galβ1,3GalNAc sequence of GSLs
in vivo [111]. Detailed data are not available for the human enzyme, which is considered involved
in the α2,3 sialylation of the Galβ1,3GlcNAc sequence necessary for constructing the tetrasaccharide
epitope of the CA19.9 antigen [112], an adhesion molecule potentially involved in cancer [113,114].
Two pathogenic variants of ST3GAL3 were found in adult members of two families reported
to suffer from non-syndromic autosomal recessive intellectual disability [115]. The A13N variant
appeared to be associated with preserved enzymatic activity in vitro and even only partial retention of
the protein in the ER.
Conversely, the other mutation, N370T, was found to determine total loss of enzymatic activity
together with substantial retention in the ER. Further, a third mutation (A320P) was reported in
four infants from a consanguineous family that were diagnosed with West syndrome, evolved to
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Lennox–Gestaut syndrome [35], which are age-dependent epileptic encephalopathic syndromes defined
by a specific electroencephalography pattern and associated with developmental arrest or regression.
Such a mutation provided a complete loss of enzymatic activity and impaired protein localization [116].
Recently, neurons differentiated from iPSc cells obtained from fibroblasts carrying the A320P
mutation [116] were studied in order to find the glycoproteins lacking sialyl-α2,3 residues, as assessed
by Maackia amurensis labeling. A defect in a single 80-kDa glycoprotein was detected in differentiated
cortical neurons, together with altered adhesion properties. In the st3gal3 KO mouse model of the
disease, the animals lack neurologic symptoms, presenting only mild immunologic anomalies [117,118].
In this case, retention in the ER of the variants suggests that they could be misfolded, irrespective
of the catalytic activity maintained, and this would be compatible with a pathogenic role of altered
proteostasis, irrespective of the lack of sialylation, on either glycoproteins or glycosphingolipids.
5. Conclusions
Recent studies on the GD/PD relationship demonstrate that GBA variants predispose individuals
to PD through molecular mechanisms that have the potential to operate in other disorders affecting
sphingolipid metabolism, leading in turn to neurodegeneration.
One such mechanism depends on the amounts of individual molecules accumulated. It has
been well proven in the case of the inflammatory role played by GlcCer through the activation of
complement in the tissues affected by type 1 GD [45]. This is also potentially relevant in conditions
where gene mutations predispose individuals to the accumulation of non-physiologic by-products,
such as lysosphingolipids in several diseases. (Table 1), deoxysphingolipids in hereditary sensory
neuropathy type 1, and ∆14-cis sphingolipids in defective desaturase activity (Table 3). Similarly,
a direct pathogenic effect is possibly due to the lack of specific products in the diseases affecting
biosynthetic enzymes, as typically seen in ST3GAL5 deficiency.
Another relevant mechanism suggested by the GBA/PD relationship involves the traffic of vesicles
towards lysosomes, affecting autophagy. The peculiar role of autophagy in the survival of neurons
is well known, as well as the pathogenic role of its impairment in neurodegeneration [119]. In PD,
α-synuclein accumulation appears strongly dependent on autophagy, as detailed in the section above.
Sphingolipid metabolism strongly interplays with neuronal autophagy, with particular relevance of
gangliosides, ceramide, SM, S1P, and GlcCer. Autophagy is impaired by increased GlcCer and SM
levels, as determined by GBA and sphingomyelinase SMPD1 deficits, but stimulated by increased
ceramide levels (reviewed in [120]) or impaired by reduced levels [59]. Some HSPs are due to impaired
sphingolipid metabolism, others to defective mitochondrial proteins, and others to gene mutations
that code proteins involved in organelle trafficking and shape [34]. One of the latter, spastin, is
considered particularly relevant in the disease pathogenesis suggesting that toxic gain-of-function
mechanisms operate in a context of a nervous system made vulnerable by haploinsufficiency [121].
A reasonable hypothesis is that any imbalance between the amounts of individual sphingolipids may
impair endocytic trafficking, affecting cargo load or autophagy directly, as proven for GBA variants.
In this regard, it is important to note that some models revealed specific impairment of mitophagy in
PD [64]. In ST3GAL5-CDG, the lack of ganglio-series gangliosides is probably accompanied by the
accumulation of globosides, and mitochondrial defects are present, sometimes reported to misdirect
the diagnosis [122], although brain mitochondria lack gangliosides [123]; we speculate that impaired
mitophagy may occur in the disease as suggested for lysosomal storage diseases [124].
Finally, GBA variants affect cell homeostasis through altered proteostasis due to ER stress or other
consequences of protein misfolding [39,48,54]. In ST3GAL3-CDG, protein variants were reported to be
improperly localized and partially retained in the ER.
A growing number of pharmacologic inhibitors of sphingolipid metabolism are available and
studied as drugs potentially suitable in human diseases [125]. Once those able to cross the blood–brain
barrier are selected, it will be possible in the future to use them to target the pathogenic mechanisms
of some neurodegenerative disorders, possibly in association with the substances potentially able to
affect lysosomal function, autophagy, and proteostasis [68,69,126].
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Table 1. Enzymes involved in sphingolipid degradation and recycling.
Enzyme Hugo Symbol Subcellular Site Disease Main Clinical Features Biochemical Features Ref
Acid ceramidase ASAH1 Lysosome
Farber disease and
spinal muscular
atrophy with
progressive
myoclonic epilepsy
Typical spectrum disease varying from
the classic triad of subcutaneous
nodules, joint contractures, and hoarse
voice to moderate or severe forms
involving hematopoietic,
gastrointestinal, respiratory, and
neurologic symptoms, including
seizures; developmental delay and
death in the early childhood.
The same Y137C mutation
provided very mild phenotype in
a patient and severe neurologic
phenotype in another. Two SNPs
are associated with schizophrenia.
Residual activity >5% is
associated with survival.
Candidate risk factor for
Parkinson´s disease (PD).
[29,73,127]
Neutral ceramidase ASAH2 Plasma membrane
None reported
Main expression in the small intestine
and colon, probable role in digestion. [128]
Alkaline ceramidases
ACER1 Endoplasmicreticulum (ER) Main expression in the skin. [129]
ACER2 Golgi apparatus
ACER3 ER and Golgiapparatus
Progressive
leukodystrophy
Developmental regression at 6–13
months, starting with peripheral
neuropathy and leading to severe
dysmorphic facial feature and
psychomotor impairment, requiring
mechanical ventilation.
Plasma accumulation of
ceramides, dihydroceramides,
glucosylceramide (GlcCer), and
lactosylceramide (LacCer).
Increased blood lactate levels.
[30]
Sphingosine kinases SPHK1
Plasma membrane
(main) None reported [130]
SPHK2 ER (main)
Sphingosine lyase SGPL1 ER
Syndromic
steroid-resistant
nephrotic syndrome
Steroid-resistant nephrotic syndrome
with facultative ichthyosis, adrenal
insufficiency, immunodeficiency, and
neurological defects.
Reduced activity and protein
mislocalization are frequent
between mutations. Ceramides
are elevated in the conditioned
culture medium of patient
fibroblasts.
[131]
Galacto-cerebrosidase GALC Lysosome Krabbe disease
Infantile onset (within 6 months).
Increased irritability, spasticity,
developmental delay along with
unexplained fever, blindness, and
deafness. Severe motor and mental
deterioration.
Poor genotype–phenotype
relationship.
Galactosyl-sphingosine
(psychosine) accumulates,
affecting endolysosomal transport
and pH. Aggregated forms of
α-synuclein reported.
[37,49,79,91]
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Table 1. Cont.
Enzyme Hugo Symbol Subcellular Site Disease Main Clinical Features Biochemical Features Ref
Gluco-cerebrosidases
GBA Lysosome Gaucher disease
Type 1 disease classically includes
inflammatory signs in visceral organs
that appear in adulthood; types 2 and 3
are instead neuronopathic, with early
onset and progression at different rates.
Recently proposed to be a spectrum
disease. Main genetic risk factor for PD
even in heterozygous carriers (see
details in the text).
Poor genotype–phenotype
relationship. GlcCer and
glucosylsphingosine accumulate,
affecting vesicle traffic and
autophagy including mitophagy,
which are also impaired by
altered proteostasis. Strong
evidence that glucocerebrosidase
(GBA) variants affect α-synuclein
accumulation (see details in
the text).
[27,33,50,54,57]
GBA2 Microsomes
HSP46/Cerebellar
ataxia with late-onset
spasticity
Early onset of motor impairment with
mental retardation, cataract, and
hypogonadism in males. MRI: cerebellar
and corpus callosum atrophy.
Loss of enzymatic activity in
almost all known mutations.
Inhibition of activity in fibroblasts
from Niemann–Pick patients
restores endolysosomal pH.
[28,44,72]
β-galactosidase GLB1 Lysosome GM1 gangliosidosis
Infantile form: early onset and rapid
progressive psychomotor deterioration,
skeletal abnormalities, visceromegaly,
and death. Juvenile and adult
phenotypes characterized by slowly
progressive neurological degeneration
and mild skeletal changes.
Poor genotype–phenotype
correlation. GM1, LacCer, and
lactosylsphingosine accumulate
causing impairment of
endolysosomal transport and pH,
autophagy, and mitochondrial
function). ER stress detected.
[81,99]
Hexosaminidase A HEXA Lysosome Tay–Sachs disease
Infantile form: early onset of
neurodevelopmental dysfunctions,
hypotonia and eye movement
abnormalities. Progression includes
dysphagia, seizures, macrocephaly, and
death until age 3.5 years.
Juvenile onset includes ataxia,
dysarthria, dysphagia, progressive
hypotonia, seizures, and death until 15
years of age.
[99]
Hexosaminidase B HEXB Lysosome Sandhoff disease
Juvenile onset form: reduced attention,
weakness, hypotonia, and progressive
psychomotor impairment.
Adult-onset form: milder phenotype
due to residual enzymatic activity.
Muscle weakness and motor symptoms.
GM2, asialo-GM2, and globoside
accumulate. Deposits of
α-synuclein reported.
[49,99]
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Table 1. Cont.
Enzyme Hugo Symbol Subcellular Site Disease Main Clinical Features Biochemical Features Ref
GM2 activator GM2A Lysosome GM2 gangliosidosis Similar to Tay–Sachs disease. [99]
α-galactosidase GLA Lysosome Fabry disease
X-linked recessive, phenotypes from
healthy to severe in women, severe to
fatal in men. Various organs potentially
involved, including peripheral and
central nervous system. Cardiovascular
involvement is frequent and at high risk
for stroke and arrhythmias.
Globotriaosylceramide and
globotriaosylsphingosine
accumulate. Activity of
respiratory chain enzymes
reduced, protein trafficking and
sorting altered,
autophagy-lysosome pathway
dysregulated. Impaired
α-synuclein degradation.
[38,76,132]
Acid sphingomyelinase SMPD1 Lysosome andsecretory
Niemann–Pick
disease types A and B
The gene is paternally imprinted.
Type A: acute, early onset with failure to
thrive and hepatosplenomegaly. Rapid
and progressive neurodegenerative
course, hypothonia and death until age
of 3 years. Cherry-red spot in the macula.
Type B: chronic, no neurologic signs.
Hepato-splenomegaly and signs of liver
failure. Impaired pulmonary function.
High levels of serum triglycerides and
LDL-cholesterol, low levels of
HDL-cholesterol. Reddish brown or
cherry red spot in the macula. SMPD1
variants are confirmed risk factor for PD.
Good genotype-phenotype
correlation. Sphingomyelin and
lysosphingomyelin
(sphingosine-phosphocoline)
accumulate. Increased levels of
cholesterol, GlcCer, LacCer, and
gangliosides. Decreased activity
levels led to α-synuclein
accumulation.
[22,36]
Neutral
sphingomyelinases
SMPD2 Plasma membrane
None reported [22]
SMPD3 ER, Golgi apparatus,and nucleus
SMPD4 ER and Golgiapparatus
SMPD5 Mitochondria andER
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Table 2. Golgi apparatus resident enzyme involved in the biosynthesis of complex sphingolipids. Note that sphingomyelin synthase SGMS2 resides in the
plasma membrane.
Enzyme Hugo Symbol Disease Inheritance Main Clinical Features Biochemical Features Ref.
Sphingomyelin synthases SGMS1 None reported [22]
SGMS2 (plasma
membrane
resident)
Osteoporosis with
skeletal dysplasia Autosomal dominant
Minor neurologic signs detectable in
some cases. Childhood onset
osteoporosis with or without cranial
sclerosis, neonatal fractures, short
stature, and spondylometaphyseal
dysplasia.
Variants are frequently mislocalized
or retained in the ER; catalytic
activity maintained by some
variants.
[23]
Glucosylceramide synthase UGCG Congenital ichthyosis Autosomal recessive
Normal growth parameters at birth, but
covered with a collodion membrane;
death at age 2 weeks because of severe
hypernatremic anuric renal failure.
Phenotype similar to that of the
keratinocyte-conditional KO mouse. [24]
UDP-Gal: GlcCer β1,4-
galactosyltransferase B4GALT6 None reported
Synthesizes lactosylceramide.
UDP-Gal:
lactosylceramideα-1,4-
galactosyl-transferase
A4GALT Synthesizes globotriosyl ceramide.
UDP-GlcNAc:
lactosylceramide
β-1,4-GlcNAc transferase
B3GNT5 Synthesizes lacto-N-triosylceramide.
GM3 synthase ST3GAL5 ST3GAL5-CDG Autosomal recessive
Normal at birth, early onset severe
neurological signs. Failure to thrive,
regression, severe hearing, visual, motor,
and cognitive impairment (see details in
the text).
Mitochondrial defects in patients.
Globosides accumulate in human
fibroblasts.
[25,100–104]
GM2/GD2/GA2 synthase B4GALNT1
Hereditary spastic
paraplegia 26
(B4GALNT1-CDG)
Autosomal recessive
Late onset motor impairment of the legs
accompanied by mild to moderate
cognitive impairment, sometimes
associated with psychiatric illness
and/or non-neurological symptoms (see
details in the text).
GM3 and GD3 accumulate in vivo
and in vitro models. [90–92]
UDP-Gal: GM2/GD2/GA2
β1,3-galactosyltransferase B3GALT4 None reported
Synthesizes gangliosides GM1,
GD1a, and GD1b.
CMP-Sial: GlcNAcβ1,3(4)
sialyltransferase ST3GAL3
Non syndromic
autosomal recessive
intellectual
disability/West syndrome
Autosomal recessive
Only intellectual disability reported
when diagnosed in adults, West
syndrome when diagnosed in early
childhood (see details in the text).
ER retention frequent in variants,
enzyme activity maintained in one
variant.
[35,115,116]
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Table 3. Endoplasmic reticulum resident enzymes involved in the initial biosynthesis of sphingolipids.
Enzyme Hugo Symbol Disease Inheritance Main Clinical Features Biochemical Features Ref.
Serine palmitoyl
transferases
SPTLC1 Hereditary sensory
neuropathy (Type 1)
Autosomal
dominant
Onset of sensory impairment spanning the second
to fifth decades, frequent motor impairment and
burning pain episodes; distal to proximal
progression. Mutations of either one or two
subunits determine identical clinical phenotypes.
Alanine and glycine used instead of
serine producing deoxysphinganine
and deoxyceramide, which have
mitochondrial toxicity in vitro.
[9,10]
SPTLC2
SPTLC3 None reported
3-keto-dihydro-
sphingosine reductase KDSR
Erythrokeratoderma or
ichtyosis with anemia and
thrombocytopenia
Autosomal
recessive
No neurologic signs. Heterogeneous skin and
hematologic symptoms; spontaneous remission
with age in some cases.
Retinoic acid therapy effective,
probably stimulating salvage pathway
from sphingosine.
[11–13]
Dihydro-ceramide
synthases
CERS1 Myoclonus epilepsy Autosomalrecessive
Ataxia at the age of one year, delay in development,
generalized tonic–clonic seizures, action myoclonus
with onset between 6 and 16 years of age. Cognitive
deterioration up to dementia.Magnetic resonance
imaging: brainstem atrophy.
[14,15]
CERS2 Progressive myoclonusepilepsy
27 kb heterozygous
deletion
Tonic–clonic seizures prevented by valproic acid,
learning disability, progressive myoclonic epilepsy,
moderate intellectually disability with dysarthria
and ataxia.
[17]
CERS3 Congenital ichthyosis Autosomalrecessive
No neurologic signs. Congenital ichthyosis
characterized by collodion membranes at birth,
generalized scaling of the skin, and mild
erythroderma.
Specific loss of ceramides with acyl
chains from C26 up to C34 in
keratinocytes.
[16]
CERS4
None reported [18]CERS5
CERS6
Dihydro-ceramide
desaturases
DEGS1 HypomyelinatingLeukodystrophy
Autosomal
recessive
Onset at 0.5–24 months. Failure to thrive,
developmental delay, epilepsy, neurogenic
muscular atrophy, severe motor arrest,
microcephaly, dystonia and severe spasticity.
MRI: hypomyelination, thin white matter,
progressive thalamic and cerebellar atrophy.
Presence of ∆14-cis sphingolipids;
inhibition of CERS ameliorates
phenotype in zebrafish model, and
reactive oxygen species (ROS) levels in
patient fibroblasts.
[20,21]
DEGS2 None reported Relevant in stratum corneum.
Involved in the metabolism of
sphingolipid containing
4-hydroxysphingosine
(phytosphingosine).
[19]
SM synthase related
protein SAMD8 None reported
Involved in the synthesis of ceramide
phosphoethanolamine. [22]
GalCer synthase UGT8 None reported
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Abbreviations
CDG Congenital disorders of glycosylation
ER Endoplasmic reticulum
GalCer Galactosylceramide
GD Gaucher disease
GlcCer Glucosylceramide
GlcSph Glucosylsphingosine
GlcNAc N-acetylglucosamine
GSL Glycosphingolipid
HSP Hereditary spastic paraplegia
LacCer Lactosylceramide
PD Parkinson disease
ROS Reactive oxygen species
SCARB2 Scavenger receptor class B member 2/lysosomal integral protein 2 (LIMP2)
SM Sphingomyelin
S1P Sphingosine-1-phosphate
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